Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Nov;20(4):303-8.
doi: 10.1055/s-2007-991029.

Preoperative optimization of Crohn's disease

Jonathan E Efron  1 , Tonia M Young-Fadok
Affiliations

Preoperative optimization of Crohn's disease

Jonathan E Efron et al. Clin Colon Rectal Surg. 2007 Nov.

Abstract

Patients with Crohn's disease often present to the surgeon for operative intervention in poor overall condition. They may be taking multiple immunomodulators to attempt to manage their disease, may have significant weight loss and evidence of malnutrition, and 10 to 30% of the time will have intraabdominal sepsis in the form of an abscess or fistula. Preoperative optimization of these patients, when possible, may decrease morbidity and mortality, and may avoid formation of stomas for fecal diversion. Enhancing nutritional status and streamlining immunomodulator therapy prior to surgery may improve outcomes. Medical management of intraabdominal sepsis with percutaneous drainage of abdominal or pelvic abscesses may decrease postoperative septic complications, and may even avert the need for surgical intervention altogether.

Keywords: Crohn's disease; immunomodulator therapy; malnutrition; percutaneous drainage; preoperative optimization.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Tay G S, Binion D G, Eastwood D, Otterson M F. Multivariate analysis suggests improved perioperative outcome in Crohn's disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. 2003;134(4):565–572. discussion 572–563. - PubMed
    1. Colombel J F, Loftus E V, Jr, Tremaine W J, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126(1):19–31. - PubMed
    1. Yamamoto T, Allan R N, Keighley M R. Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum. 2000;43(8):1141–1145. - PubMed
    1. Marchal L, D'Haens G, Assche G Van, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther. 2004;19(7):749–754. - PubMed
    1. Mor I, Sherr B. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum. 2007;50(5):734. - PubMed